WO1994018170A1 - Use of phenyl heteroaryl ureas as 5ht2c receptor antagonists and urea compounds - Google Patents
Use of phenyl heteroaryl ureas as 5ht2c receptor antagonists and urea compounds Download PDFInfo
- Publication number
- WO1994018170A1 WO1994018170A1 PCT/EP1994/000189 EP9400189W WO9418170A1 WO 1994018170 A1 WO1994018170 A1 WO 1994018170A1 EP 9400189 W EP9400189 W EP 9400189W WO 9418170 A1 WO9418170 A1 WO 9418170A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- urea
- pyridyl
- quinolinyl
- chloro
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
Definitions
- This invention relates to a method of treatment of certain CNS disorders.
- WO 92/05170 describes ce ⁇ ain area derivatives which are described as possessing 5HT ⁇ c receptor antagonist activity.
- the 5HT ⁇ c receptor has recently been reclassified as the 5HT2C receptor [P. Hartig et al.. Trends in Pharmacological Sciences (TIPS) 1993].
- 5HT2C receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, obsessive compulsive disorders, migraine, anorexia, Alzheimers disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
- the present invention provides the use of a compound of formula (I) or a salt thereof:
- P represents a quinoline or isoquinoline residue or a 5- or 6-membered aromatic heterocyclic ring containing up to three heteroatoms selected from nitrogen, oxygen or sulphur;
- R 1 is hydrogen, Cj.g alkyl, halogen, NR 5 R 6 or OR 7 where R 5 , R 6 and R 7 are independently hydrogen or C ⁇ _ ( - alkyl;
- R2 and R**- * are independently hydrogen or Cj.g alkyl
- R 4 is hydrogen, C ⁇ . ( , alkyl, CF3, nitro, cyano, acyl, halogen, NR 5 R 6 , OR 7 or CO2 7 where R--, R-- and R 7 are independently hydrogen or C ⁇ g alkyl as defined for R 1 ; and n is 1, 2 or 3, in the manufacture of a medicament for the treatment or prophylaxis of CNS disorders.
- Cj.galkyl groups whether alone or as part of another group, can be straight chain or branched.
- R ⁇ is hydrogen or methyl.
- R2 and R-- are hydrogen.
- Suitable moieties when the ring P is a 5- or 6-membered aromatic heterocyclic ring include pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, isothiazolyl, isoxazolyl, thiadiazolyl and triazolyl.
- P is pyridyl attached to the urea nitrogen at position 3 or 4; or P is quinoline attached to the urea nitrogen at position 3, 4 or 6, preferably at position 4.
- n is 1 or 2.
- the R 4 groups can be the same or different.
- the phenyl ring is mono-substituted and R 4 is CF3 or -NMe2
- -OMe (preferably in the meta or para position); CO2Et (preferably in the meta position) or the phenyl ring is preferably di substituted with meta chloro and para methyl.
- Preferred compounds of formula (I) include:
- N-(3-Chloro-4-methylphenyl)-N -(3-pyridyl) urea N-(3-Chloro-4-methylphenyl)-N -(4-pyridyl) urea
- N-(3-Pyridyl)-N'-(3-(trifluoromethyl)phenyl)urea N-(3-Methylphenyl)-N'-(3-pyridyl)urea
- N-(4-Chlorophenyl)-N'-(3-pyridyl)urea N-(3-Chlorophenyl)-N'-(3-pyridyl)urea
- N-(3-Hydroxyphenyl)-N'-(2-methyl-4-quinolinyl)urea N-(3-Bromophenyl)-N'-(3-pyridyl)urea, N-(3,4-Dichlorophenyl)
- the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
- acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
- Compounds of formula (I) may also form N-oxides or solvates such as hydrates, and the invention also extends to these forms.
- Certain compounds of formula (I) may exist tautomerically in more than one form.
- the invention extends to these and any other tautomeric forms and mixtures thereof.
- Certain compounds of formula (I) are capable of existing in stereoisomeric forms including enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
- the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
- Certain compounds of formula (I) are novel and form a further aspect of the invention. Particularly preferred novel compounds include those listed above and exemplified herein.
- the invention further provides a method of treatment or prophylaxis of CNS disorders, in particular anxiety, depression, migraine, anorexia, obsessive compulsive disorders,
- the invention also provides novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of anxiety, depression, migraine, anorexia, obsessive compulsive disorders, Alzheimer's disease, sleep disorders, bulimia, panic attacks, withdrawal from drug abuse, schizophrenia and/or disorders associated with spinal trauma and/or head injuries.
- the present invention also provides a pharmaceutical composition, which comprises novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
- Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
- the tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
- fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
- T e compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
- the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
- the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- composition may contain from 0.1 % to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
- suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.01 to 100 mg/kg; and such therapy may extend for a number of weeks or months.
- the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises
- a and B contain the appropriate functional group(s) necessary to form the moiety, -NR2 CONR- ⁇ when coupled, the variables R - . R 2' , R 3' , and R 4 are R 1 , R 2 . R 3 , and R 4 respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, converting any R ⁇ , R 2 , R 3 and R 4 , when other than R-, R 2 , R 3 and R 4 respectively to R-, R 2 , R 3 and R 4 , interconverting R ⁇ , R 2 . R 3 , and R 4 and forming a pharmaceutically acceptable salt thereof.
- Suitable examples of groups A and B include:
- A is -NR 2 COL and B is -NHR 3'
- A is -NHR 2' and B is NR 3 COL
- R 2 and R 3 are as defined above and L is a leaving group.
- suitable leaving groups L include halogen such as chloro, bromo, imidazole or phenoxy or phenylthio optionally substituted for example with halogen.
- reaction is suitably carried out in an inert solvent for example dichloromethane or toluene at ambient temperature.
- an inert solvent for example dichloromethane or toluene at ambient temperature.
- the reaction is suitably carried out in an inert solvent such as dichloromethane at ambient temperature optionally in the presence of a base, such as triethylamine or in dimethylformamide at ambient or elevated temperature.
- a base such as triethylamine or in dimethylformamide at ambient or elevated temperature.
- a is halogen and B is NR 3 CONHR 2 the reaction is suitably carried out in an inert solvent such as toluene at elevated temperature, optionally in the presence of a base.
- Suitable examples of groups R ⁇ and R 4 which are convertible to R* and R 4 alkyl groups respectively, include acyl groups which are introduced conventionally and may be converted to the corresponding alkyl group by conventional reduction, such as using sodium borohydride in an inert solvent followed by hydrogenolysis in an inert solvent. Hydrogen substituents may be obtained from alkoxycarbonyl groups which may be converted to hydrogen by hydrolysis and decarboxylation.
- R-, R 2 , R 3 and R 4 Interconversions of R-, R 2 , R 3 and R 4 are carried out by conventional procedures.
- R 2 is ⁇ . alkyl and R 3 is hydrogen it is possible to introduce a C ] _6 alkyl group at the R 3 position by conventional alkylation using 1 molar equivalent of a C j .g alkyl haiide and 1 molar equivalent of a suitable base in an inert solvent.
- Suitable examples of a group R 2 and R 3 which is convertible to R 2 and R 3 include alkoxycarbonyl and benzyl or ⁇ r ⁇ -methoxybenzyl which are converted to R 2 and R 3 is hydrogen using conventional conditions.
- R ! halo and R 4 halo may be introduced by selective halogenation of the ring P or the benzene ring respectively using conventional conditions.
- Compounds of formula (II) in which A is NHR 2 are known compounds or can be prepared analogously to known compounds, see, for example, WO 92/05170 (SmithKline Beecham pic).
- A is amino, with phosgene or a phosgene equivalent, in the presence of excess base in an inert solvent.
- A is acylazide (i.e. CON3), via the nitrene, by thermal rearrangement using conventional conditions (ref L.S. Trifonov et al, Helv. Chim. Acta 1987 7_ ⁇ 262).
- iii) A is CONH2, via the nitrene intermediate using conventional conditions.
- phosgene equivalents include triphosgene, carbonyldiimidazole, phenyl chloroformate and phenyl chorothioformate.
- Compounds of formula (II) in which A is NR2'COL may be prepared by reacting a compound of formula (II) in which A is NHR2' with phosgene or a phosgene equivalent in an inert solvent, at low temperature, if necessary in the presence of one equivalent of a base such as trithylamine.
- Compounds of formula (II) in which A is halogen and R4' is hydrogen are commercially available.
- salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.
- N-oxides may be formed conventionally by reaction with hydrogen peroxide or percarboxylic acids.
- the title compound (E4) was prepared in 56% yield from 6-aminoquinoline and phenylisocyanate following a procedure similar to that in Example 1. Free base precipitated from the reaction mixture and was recrystallised from ethanol.
- 3-Methoxyphenyl isocyanate (0.83 ml, 6.3 mmol) in dry dichloromethane (30 ml) was added slowly to 4-aminoquinaldine (lg, 6.3 mmol) in dry toluene (30 ml) under a nitrogen atmosphere, and left to stir at room temperature for 19h.
- the precipitate which formed was filtered off, washed with cold 1 : 1 toluene/dichloromethane and dried in vacuo.
- the crude product was purified by recrvstallization from ethanol to give the title compound (0.99g, 51%) as a white solid, m.p. 191-193°C.
- 3-Ethoxyc r onylphenyl isocyanate (lg, 5.2 mmol) in dry dichloromethane (30 ml), was added slowly to 4-aminoquinaldine (0.83g, 5.2 mmol) in dry toluene (30 ml), under a nitrogen atmosphere, and left to stir at room temperature for 19h.
- the precipitate which formed was filtered off, washed with cold 1:1 toluene/dichloromethane and dried in vacuo.
- the crude product was chromatographed on silica gel, using dichloromethane as the eluant to give the title compound (0.78g, 43%) as white crystals, m.p. 165-170°C.
- Nicotinoyl azide (0.40g, 2.7 mmol) was stirred at reflux under nitrogen atmosphere in dry toluene (10 ml) for lh, with gas evolution. The solution was cooled to ambient temperature, and 3-chloro-4-methylaniline (0.30 ml, 2.4 mmol) was added. The suspension so formed was stirred for 1 h, when the solid was filtered off, washed with 1 : 1 toluene/dichloromethane, and dried in vacuo at 70°C. This gave the free base of the title compound (0.64g, 85%) as a white solid.
- N-(3-Chloro-4-methyl)-N -(3-pyridyl) urea (0.55g, 2.1 mmol) was dissolved in hot ethanol (10 ml), and a solution of hydrogen chloride in ether (ca. 0.9M, 2.5 ml, ca. 2.3 mmol) was added. The suspension was cooled to ambient temperature, and the solid was filtered off, washed with cold ethanol, and dried in vacuo at 70°C. This gave the title compound (0.62g, 76%) as a white solid, m.p. 214.5-216°C.
- 3-Chloro-4-methvlaniline (0.65 ml, 5.3 mmol) was stirred under nitro ⁇ en in dichloromethane ( 15 ml) at 0°C as triethylamine (0.82 ml, 5.9 mmol) was added. To this mixture was then added phosgene in toluene solution (1.93M, 4.1 ml, 7.9 mmol). After stirring at 0°C for 0.5h, triethylamine (1.6 ml, 1 1.8 mmol) was added and, after a further 0.5h, 4-aminopyridine (0.50g, 5.3 mmol) w*_s added.
- N-(3-Chloro-4-methylphenyl)-N -(4-pyridyl) urea (1.03g, 3.9 mmol) was treated with hydrogen chloride using the method of Example 11. This gave the title compound (0.95g, 81 %) as a white solid, m.p. 235-240°C (decomp.).
- the title compound was prepared in 91% yield from 3-pyridyl isocyanate and 3- aminobenzotrifluoride; m.p. 180-184° C.
- the title compound was prepared in 87% yield from 3-aminopyridine and m-tolyl isocyanate, followed by salt formation with HC1; m.p. 182-183° C.
- the title compound was prepared in 29% yield from 3-aminopyridine, 1,1'- carbonyldiimidazole and 4-chloroaniline; m.p. 207-209° C
- the title compound was prepared in 75% yield from 3-bromopyridine and 3-pyridyl isocyanate: m.p. 190-193° C.
- the title compound was prepared in 65% yield from 3,4-dichloroaniline and 3-pyridyl isocyanate; m.p. 206° C-210° C.
- the title compound was prepared in 85% yield from 3-fluoro-4-methylaniline and 3- pyridyl isocyanate; m.p. 190-191 ° C.
- the title compound was prepared in 73% yield from 3-chloro-4-tert-butylaniline & 3- pyridyl isocyanate; m.p. 190° C-193 0 C.
- N-(3-Hydroxy-4-carboxyphenyl)-N'-(3-pyridyl)urea was prepared in 69% yield from 4- aminosalicylic acid and 3-pyridyl isocyanate in DMF/toluene. This material (0.37g, 1.4 mmol) was then stirred in methanol (20 ml) as thionyl chloride (2 ml) was cautiously added. The suspension was stirred at reflux under argon for 2 days, and evaporated to dryness. The residue was suspended in saturated sodium hydrogen carbonate solution, and the solid was filtered off, washed with water, dried, and recrystallised from ethanol/petroleum ether (b.p. 60-80° C), giving the title compound (0.16g, 41%) as a white solid, m.p. 199-200° C. NMR (DMSO d ⁇ ) ⁇ :
- 5-HT? antagonists may have a number of therapeutic indications including the treatment f anxiety, migraine, depression, feeding disorders and obsessive compulsion disorders. (Curzon and Kennett, 1990; Fozard and Gray, 1989) and Alzheimer's Disease (Lawlor, 1989, J. Arch. Gen. Psychiat. Vol. 46 p.542).
- the affinity of test drugs for the 5-HT2C binding site can be determined by assessing their ability to displace [ 3 H]-mesulergine from 5-HT2 clones expressed in 293 cells (Julius et al., 1988). The method employed was similar to that of Pazos et al, 1984.
- the cells suspension (50ml) was incubated with [ 3 H]-mesulergine (0.5nM) in Tris HC1 buffer (pH 7.4) at 37°C for 30 minutes. Non-specific binding was measured in the presence of mianserin (10""M). Ten concentrations of test drug (3 x 10"9 to 10 " M final concentration) were added in a volume of 50ml. The total assay volume was 500ml. Incubation was stopped by rapid filtration using a Brandel cell harvester and radioactivity measured by scintillation counting. The IC50 values were determined using a four parameter logistic program O eLean 1978) and the pKj (the negative logarithm of the inhibition constant) calculated from the Cheng Prusoff equation where:
- Kd Affinity of mesulergine for 5-HT-J C binding sites.
- the compound of Example 7 has a pKi of 8.28.
- the compound of Example 11 has a pKi of 7.79.
- mCPP-induced hypolocomotion was measured in automated locomotion cages of dimensions 56 cm long x 1614 cm wide x 25 cm high and made of black perspex. Two photobeams traversed the width of the cages at either end at ground level. Sequential breaking of these beams allowed the measurement of cage transits.
- mice Male Sprague Dawley rats (200-250g) (Charles River) were housed in groups of six. They were given drugs orally lh pretest and 40 mins later mCPP (7 mg/kg i.p.). After a further 20 min they were placed in individual automated cages in groups of four under red light in an adjacent room. After 10 min the test was terminated. Reversal of mCPP-induced hypolocomotion was considered as evidence of in vivo central 5-HT2C receptor antagonist properties.
- the compound of Example 11 had an ID50 of 78 mg/kg p.o.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6517583A JPH08506114A (en) | 1993-02-05 | 1994-01-25 | Use of phenylheteroaryl ureas as c-receptor antagonists and urea compounds |
EP94905697A EP0682656A1 (en) | 1993-02-05 | 1994-01-25 | Use of phenyl heteroaryl ureas as 5ht 2c? receptor antagonists and urea compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9302275.4 | 1993-02-05 | ||
GB939302275A GB9302275D0 (en) | 1993-02-05 | 1993-02-05 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994018170A1 true WO1994018170A1 (en) | 1994-08-18 |
Family
ID=10729906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1994/000189 WO1994018170A1 (en) | 1993-02-05 | 1994-01-25 | Use of phenyl heteroaryl ureas as 5ht2c receptor antagonists and urea compounds |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0682656A1 (en) |
JP (1) | JPH08506114A (en) |
GB (1) | GB9302275D0 (en) |
WO (1) | WO1994018170A1 (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000047580A2 (en) * | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives |
US6242453B1 (en) | 1999-02-22 | 2001-06-05 | Boehringer Ingelheim Pharmaceuticals, Inc | Polycyclo heterocyclic derivatives as antiinflammatory agents |
US6297381B1 (en) | 1999-03-12 | 2001-10-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US6319921B1 (en) | 1999-01-19 | 2001-11-20 | Boerhinger Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compound as antiinflammatory agents |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
US6358945B1 (en) | 1999-03-12 | 2002-03-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6432995B2 (en) | 1997-11-03 | 2002-08-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
WO2002085857A2 (en) * | 2001-04-20 | 2002-10-31 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US6492393B1 (en) | 1999-11-16 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6699879B1 (en) * | 1999-02-12 | 2004-03-02 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
US6743788B2 (en) | 2001-05-25 | 2004-06-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds |
US6753426B2 (en) | 1999-07-09 | 2004-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polymorph and process for preparing same |
EP1473292A1 (en) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US6852717B2 (en) | 2001-05-16 | 2005-02-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US7041669B2 (en) | 2002-02-25 | 2006-05-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
CZ299836B6 (en) * | 1997-12-22 | 2008-12-10 | Bayer Corporation | Aryl- and heteroaryl-substituted heterocyclic ureas, their use and pharmaceutical compositions in which the ureas are comprised |
WO2009035951A2 (en) * | 2007-09-11 | 2009-03-19 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8063081B2 (en) | 2002-06-27 | 2011-11-22 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
US8207166B2 (en) | 2004-04-30 | 2012-06-26 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US9181188B2 (en) | 2002-02-11 | 2015-11-10 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
CN109645019A (en) * | 2017-10-11 | 2019-04-19 | 中国疾病预防控制中心寄生虫病预防控制所 | The purposes of pyridine carbamide compounds with ovicidal trait |
CN114600893A (en) * | 2022-04-15 | 2022-06-10 | 江西省农业科学院植物保护研究所 | Flupirouron floating granule and preparation method and application thereof |
US11833136B2 (en) | 2018-06-12 | 2023-12-05 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880817A (en) * | 1987-06-09 | 1989-11-14 | Ortho Pharmaceutical Corporation | O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
EP0354994A2 (en) * | 1988-07-12 | 1990-02-21 | Takeda Chemical Industries, Ltd. | Quinoline derivatives, their production and use |
WO1992005170A1 (en) * | 1990-09-13 | 1992-04-02 | Beecham Group Plc | Indole ureas as 5 ht receptor antagonist |
JPH04173701A (en) * | 1990-11-06 | 1992-06-22 | Hokko Chem Ind Co Ltd | Chemical injury-mitigative agent for paddy herbicide |
EP0515684A1 (en) * | 1990-02-14 | 1992-12-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of denatured ldl formation |
EP0540854A2 (en) * | 1991-09-10 | 1993-05-12 | Sansho Seiyaku Co., Ltd. | Preparation for promoting hair growth |
WO1993018028A1 (en) * | 1992-03-12 | 1993-09-16 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
-
1993
- 1993-02-05 GB GB939302275A patent/GB9302275D0/en active Pending
-
1994
- 1994-01-25 JP JP6517583A patent/JPH08506114A/en active Pending
- 1994-01-25 WO PCT/EP1994/000189 patent/WO1994018170A1/en not_active Application Discontinuation
- 1994-01-25 EP EP94905697A patent/EP0682656A1/en not_active Withdrawn
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880817A (en) * | 1987-06-09 | 1989-11-14 | Ortho Pharmaceutical Corporation | O-functionalized derivatives of substituted isoquinolin-3-ols having cardiotonic and/or phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
EP0354994A2 (en) * | 1988-07-12 | 1990-02-21 | Takeda Chemical Industries, Ltd. | Quinoline derivatives, their production and use |
EP0515684A1 (en) * | 1990-02-14 | 1992-12-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibitor of denatured ldl formation |
WO1992005170A1 (en) * | 1990-09-13 | 1992-04-02 | Beecham Group Plc | Indole ureas as 5 ht receptor antagonist |
JPH04173701A (en) * | 1990-11-06 | 1992-06-22 | Hokko Chem Ind Co Ltd | Chemical injury-mitigative agent for paddy herbicide |
EP0540854A2 (en) * | 1991-09-10 | 1993-05-12 | Sansho Seiyaku Co., Ltd. | Preparation for promoting hair growth |
WO1993018028A1 (en) * | 1992-03-12 | 1993-09-16 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
Non-Patent Citations (2)
Title |
---|
P. FLUDZINSKI ET AL: "2,3-dialkyl(dimethylamino)indoles: Interaction with 5HT1,5HT2 and rat stomach fundal serotonin receptors.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 11, 1986, WASHINGTON US, pages 2415 - 2418 * |
PATENT ABSTRACTS OF JAPAN vol. 16, no. 473 (C - 0991) 2 October 1992 (1992-10-02) * |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1473292A1 (en) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US6432995B2 (en) | 1997-11-03 | 2002-08-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds and their use as anti-inflammatory agents |
CZ299836B6 (en) * | 1997-12-22 | 2008-12-10 | Bayer Corporation | Aryl- and heteroaryl-substituted heterocyclic ureas, their use and pharmaceutical compositions in which the ureas are comprised |
US6337338B1 (en) | 1998-12-15 | 2002-01-08 | Telik, Inc. | Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US6333325B1 (en) | 1999-01-19 | 2001-12-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method of treating cytokine mediated diseases or conditions |
US6372773B1 (en) | 1999-01-19 | 2002-04-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6329415B1 (en) | 1999-01-19 | 2001-12-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6506748B2 (en) | 1999-01-19 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6319921B1 (en) | 1999-01-19 | 2001-11-20 | Boerhinger Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compound as antiinflammatory agents |
US6596730B1 (en) | 1999-02-12 | 2003-07-22 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives |
WO2000047580A3 (en) * | 1999-02-12 | 2000-12-21 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives |
US6699879B1 (en) * | 1999-02-12 | 2004-03-02 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
WO2000047580A2 (en) * | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives |
US6242453B1 (en) | 1999-02-22 | 2001-06-05 | Boehringer Ingelheim Pharmaceuticals, Inc | Polycyclo heterocyclic derivatives as antiinflammatory agents |
US6297381B1 (en) | 1999-03-12 | 2001-10-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US6358945B1 (en) | 1999-03-12 | 2002-03-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6656933B2 (en) | 1999-03-12 | 2003-12-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6660732B2 (en) | 1999-03-12 | 2003-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6476023B1 (en) | 1999-03-12 | 2002-11-05 | Boehringen Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US7026476B2 (en) | 1999-03-12 | 2006-04-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Intermediate arylamine compounds |
US7019006B2 (en) | 1999-03-12 | 2006-03-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6753426B2 (en) | 1999-07-09 | 2004-06-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polymorph and process for preparing same |
US6492393B1 (en) | 1999-11-16 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US7241758B2 (en) | 1999-11-16 | 2007-07-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
WO2002085857A2 (en) * | 2001-04-20 | 2002-10-31 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
WO2002085857A3 (en) * | 2001-04-20 | 2003-01-16 | Bayer Ag | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US6852717B2 (en) | 2001-05-16 | 2005-02-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6743788B2 (en) | 2001-05-25 | 2004-06-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds |
US9181188B2 (en) | 2002-02-11 | 2015-11-10 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
US7041669B2 (en) | 2002-02-25 | 2006-05-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
US8063081B2 (en) | 2002-06-27 | 2011-11-22 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US8207166B2 (en) | 2004-04-30 | 2012-06-26 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
US8138185B2 (en) | 2007-01-09 | 2012-03-20 | Novo Nordisk A/S | Urea glucokinase activators |
WO2009035951A3 (en) * | 2007-09-11 | 2009-10-29 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
WO2009035951A2 (en) * | 2007-09-11 | 2009-03-19 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
CN109645019A (en) * | 2017-10-11 | 2019-04-19 | 中国疾病预防控制中心寄生虫病预防控制所 | The purposes of pyridine carbamide compounds with ovicidal trait |
CN109645019B (en) * | 2017-10-11 | 2021-12-24 | 中国疾病预防控制中心寄生虫病预防控制所 | Use of pyridylurea compound with molluscicidal activity |
US11833136B2 (en) | 2018-06-12 | 2023-12-05 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
US11974989B2 (en) | 2018-06-12 | 2024-05-07 | Vtv Therapeutics Llc | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
CN114600893A (en) * | 2022-04-15 | 2022-06-10 | 江西省农业科学院植物保护研究所 | Flupirouron floating granule and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP0682656A1 (en) | 1995-11-22 |
JPH08506114A (en) | 1996-07-02 |
GB9302275D0 (en) | 1993-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994018170A1 (en) | Use of phenyl heteroaryl ureas as 5ht2c receptor antagonists and urea compounds | |
US5508288A (en) | Indole derivatives as 5HT1C antagonists | |
CA2559733C (en) | Inhibitors of histone deacetylase | |
JP3095521B2 (en) | Piperazine derivative | |
WO1994014801A1 (en) | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists | |
DE60222396T2 (en) | N- (2-ARYLETHYL) BENZYLAMINE AS 5-HT6 RECEPTOR ANTAGONIST | |
KR100360633B1 (en) | 6-Phenylpyridyl-2-amine Derivatives Useful as NOS Inhibitors | |
AU779034B2 (en) | Benzanilides as potassium channel openers | |
US7273877B2 (en) | 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | |
RU2411237C2 (en) | PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS mGluR5 ANTAGONISTS | |
US5866586A (en) | CNS-active pyridinylurea derivatives | |
JP2001526643A (en) | Bicyclic aryl or heterocyclic rings, including compounds having combined 5HT1A, 5HT1B and 5HT1D receptor antagonist activity | |
JPH04273870A (en) | 2-aminopyrimidine-4-carboxamide derivative, its preparation and medical use | |
WO1997008167A1 (en) | 5ht2c and 5ht2b antagonists | |
CA2299286A1 (en) | Bicyclic compounds as ligands for 5-ht1 receptors | |
EP0691973A1 (en) | THIENO-INDOLE DERIVATIVES AS 5HT2c AND 5HT2b ANTAGONISTS | |
US6313145B1 (en) | Indoline derivatives useful as 5-HT-2C receptor antagonists | |
CA2043604A1 (en) | Pyridinylpiperazine derivatives | |
KR20030024919A (en) | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide | |
US6369060B1 (en) | Indoline derivatives useful as 5-HT-2C receptor antagonists | |
WO1997011054A1 (en) | Benzoic acid compounds and medicinal use thereof | |
US6031097A (en) | 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands | |
WO1997032854A1 (en) | 2-sulfinylnicotinamide derivatives, intermediate thereof, process for producing 2-sulfinylnicotinamide derivatives, and medicinal composition containing the same as active ingredient | |
JPH0741481A (en) | Amphoteric tricyclic compound | |
RU2211216C2 (en) | Derivatives of amides and urea as inhibitors of reuptake of 5-ht and ligands of 5-ht1b/1d |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994905697 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 500842 Date of ref document: 19950804 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1994905697 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994905697 Country of ref document: EP |